Evolent Health, Inc. EVH
Other Consumer Services · IPO 2015 · data as of November 13, 2026
Evolent Health, Inc. (EVH) is a consumer discretionary company listed in the US with a market value of about $554M. In the twelve months to September 30, 2026 it had revenue of $2.3B and net income of -$508M, a net margin of -21.7%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (1/5).
Key numbers: a price to free cash flow of 15.1, 5-year revenue growth of 15% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 17% above the current price.
About Evolent Health
Evolent Health is listed in the US and classified in other consumer services, IPO year 2015. Revenue went from $254M in 2016 to $1.9B in 2025, growth of about 24.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 22% over three years (dilution for shareholders).
Score: 1.2 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3B | $1.9B | $2.6B | $2.0B | $1.4B | $908M | $925M | $846M | $627M | $435M | $254M |
| Net income | -$508M | -$535M | -$62M | -$113M | -$19M | -$38M | -$334M | -$302M | -$53M | -$61M | -$160M |
| Free cash flow | $37M | — | — | — | — | — | — | -$78M | -$60M | -$56M | -$51M |
| EPS (diluted) | $-4.54 | $-5.07 | $-0.81 | $-1.28 | $-0.20 | $-0.44 | $-3.94 | $-3.67 | $-0.68 | $-0.94 | $-3.55 |
| Net margin | -21.7% | -28.5% | -2.4% | -5.8% | -1.4% | -4.1% | -36.1% | -35.7% | -8.4% | -14.0% | -62.8% |
| ROIC | — | -29.2% | -2.3% | -2.3% | 0.2% | -3.4% | -26.7% | -22.2% | -2.8% | -5.9% | -27.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $6.00, 22% above the current price; targets range from $3.00 to $8.00; the consensus rating is “Buy”; expected EPS is $0.23 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Evolent Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 17% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Evolent Health pay a dividend?
Not currently.
Is Evolent Health a good stock to buy?
We do not give buy or sell advice. Evolent Health scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.